Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients

Cardiovascular (CV) toxicities of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib may limit use of this effective therapy in patients with chronic lymphocytic leukemia (CLL). Acalabrutinib is a second-generation BTK inhibitor with greater BTK selectivity. This analysis characterizes pooled CV a...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Jennifer R., Byrd, John C., Ghia, Paolo, Sharman, Jeff P., Hillmen, Peter, Stephens, Deborah M., Sun, Clare, Jurczak, Wojciech, Pagel, John M., Ferrajoli, Alessandra, Patel, Priti, Tao, Lin, Kuptsova-Clarkson, Nataliya, Moslehi, Javid, Furman, Richard R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2021
Materias:
Article - Chronic Lymphocytic Leukemia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152976/
https://www.ncbi.nlm.nih.gov/pubmed/34587719
http://dx.doi.org/10.3324/haematol.2021.278901

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152976/
https://www.ncbi.nlm.nih.gov/pubmed/34587719
http://dx.doi.org/10.3324/haematol.2021.278901

Ejemplares similares